Can coronavirus test-maker Novacyt still make you rich?

Coronavirus test-producer Novacyt (LON:NCYT) has likely made some savvy small-cap investors very wealthy. Could it still make money for new holders?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Small-cap stocks can generate life-changing returns if you possess the skill or luck to buy them at the right time. That’s certainly been the case to date with coronavirus test-producer Novacyt (LSE: NCYT).

At the beginning of 2020, shares in the market minnow were changing hands for just 14p each. At the close yesterday, the very same stock was trading at 426p, so some investors will have made a lot of money.  

Will this form continue? Today’s update from the company was certainly encouraging. That said, I’d be wary of becoming excessively bullish on the shares if I were thinking of buying now.

Novacyt in demand 

Taking into account its agreement with the UK Department of Health and Social Care and collaborations with GlaxoSmithKline, AstraZeneca, and The University of Cambridge, the clinical diagnostics specialist announced it had generated £90m worth of orders for its Covid-19 test. 

As a further sign of just how much demand there is, the company went on to remark it’s now supplying the test to “more than 100 countries” with new approvals having just arrived from Ecuador and Malaysia. What’s more, the firm also spoke of “evaluating potential options to further expand its presence” in the US.

Of course, orders are only good if they can be fulfilled. Earlier this month, Novacyt said it would increase manufacturing capacity to roughly 8m tests per month. Today, it revealed it expects to meet this output in June. In addition to its two manufacturing sites, the company has also signed deals with six other manufacturers, allowing it to scale-up beyond this number when needed.

CEO Graham Mullis was understandably bullish, commenting that the visibility on sales was “transformational” for the company. He also said this demand “could continue for some months.

Today’s news was undeniably positive. As great as all this sounds, however, I’m beginning to wonder if the ‘smart money’ has already been made.

Priced in?

Novacyt’s share price was up a few percent in the first few minutes of trading. That’s nothing like the gains seen in previous trading days. This suggests to me the market had already priced in much of today’s statement. 

This reaction highlights the problem with small-cap investing. Since a lot of these companies are still loss-making (Novacyt being an example), all momentum rests on hope and hype. That’s fine if you manage to time your entry well, but it can be testing when investors begin taking profits. 

Although they’re available for 436p, as I type, Novacyt’s shares were trading as high as 491p in mid-April. Had you bought at the peak, you’d now be 11% underwater. In the meantime, more established, profitable and liquid (easily traded) FTSE 100 or FTSE 250 stocks would have made you a lot of cash in the recent rally.

Don’t get greedy

Novacyt’s gains over the last couple of months have been nothing short of remarkable. Notwithstanding this, I’d caution anyone from buying a lot of the stock now. With the next stage of the pandemic hard to accurately predict, I think there’s still potential for people to lose their shirts if they chase gains and go ‘all-in’. 

If you simply must invest, I’d advise doing so with money that you can afford to lose. Put the rest of your cash in quality stocks that have rewarded investors over the long term

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand of a mature man opening a safety deposit box.
Investing Articles

If I’d invested £5k in red hot BAE Systems shares 5 years ago here’s what I’d have today

BAE Systems shares have smashed the FTSE 100 for years and Harvey Jones is keen to buy more as they…

Read more »

Investing Articles

How I’d aim to earn £16,100 in passive income a year by investing £20k in a Stocks and Shares ISA

Harvey Jones is building a portfolio of high-yielding FTSE 100 dividend stocks that should give him a high and rising…

Read more »

Investing Articles

Down 8% in a month! The BP share price is screaming ‘buy, buy, buy’ at me right now 

When crude oil falls, the BP share price invariably follows. Harvey Jones is wondering whether this is the right point…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Could the 9.8% M&G dividend yield get even bigger?

Christopher Ruane reckons that, although the M&G dividend yield is already close to a double-digit percentage, it could get better…

Read more »

Investing Articles

How much passive income could I earn by putting £380 a month into a Stocks and Shares ISA?

Christopher Ruane explains how he'd aim to turn a Stocks and Shares ISA into four-figure passive income streams each year.

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 passive income stocks I’m buying before an interest rate cut

With the market expecting interest rates to fall in August, time might be running out for investors looking to buy…

Read more »

Investing Articles

If I’d bought Rolls-Royce shares a year ago, here’s what I’d have now

Rolls-Royce shares have been the big FTSE 100 success story of the past 12 months and more. And there's still…

Read more »

Young female analyst working at her desk in the office
Investing Articles

If the Dow’s heading for 60,000 by 2030, can the FTSE 100 index hit 12,000?

Strategist Ed Yardeni predicts a 50% rise for America’s Dow Jones Industrial Average over six years. Can the FTSE 100…

Read more »